Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
Tech Nation: My Creations Have Upgrade Panels
Chapter 136

Angels to Hundreds of Millions of Sufferers Worldwide, Lin Feng's Apotheosis!

1,638 words 5 min read 0 views 2mo ago Source ​
Skip to the end of the chapter
Prev
Next

This knowledge is mainly divided into four parts, the first part being the risk assessment.

Among these, the knowledge of the new GOTI Off-target Detection Technology invented by Professor Zuo Wei in 2019 in his previous life was directly instilled into Lin Feng's mind.

From then on, Xingtu Gene Company could easily detect and assess the off-target probability of gene editing, directly improving the safety and risk of Gene Editing Technology.

The second part follows, which is the whole-body cellular gene editing part.

There are currently three methods worldwide for editing genes in cells throughout the body.

The first method is to use Plasmid Transfection Method to construct plasmids expressing sgRNA, crRNA, and cas9 protein, and then transfect the plasmids into cells.

This was the original invention and the simplest method, but its fitting efficiency was also the lowest.

It is difficult to apply to the vast number of cells in an adult's body, so even gene editing can only modify the genes of a small portion of the body's cells.

Therefore, this method has been phased out, and its only use is in conjunction with cloning technology.

After all, cloning technology itself involves a cell dividing and developing into an adult, so a low chimerism rate doesn't affect anything.

The second method is Viral Transduction Method, which is currently the mainstream gene editing method being researched by major research institutions.

This Viral Transduction Method involves editing the virus's genes to integrate sgRNA, crRNA, and sequences expressing the Cas9 protein into the virus.

This allows the virus to invade and infect all cells in an adult's body, editing and modifying the genes of those cells.

The process involves first knocking out a predetermined gene fragment, then inserting the edited gene, and finally using a specific virus or drug to clear the virus from the body, ultimately achieving the goal of gene editing.

The advantage of this method is that once a virus is edited, it can be allowed to grow and expand on its own, resulting in very low production and medical costs.

However, the fatal flaw of this method is that it causes a severe immune rejection reaction, which can lead to symptoms such as colds, fever, and pain. If one is not careful, it can cause sudden death.

The previous EBT-001 gene therapy drug used this method, and the unexpected deaths of some monkeys proved the dangers of the Viral Transduction Method.

In addition, this Viral Transduction Method also carries a certain off-target risk, which can cause the edited virus to randomly knock out normal genes, and eventually there is a certain probability that it will transform into cancer cells.

In addition, there is a hidden flaw, which is that the virus can breach the human body's cellular defenses.

Naturally, a large number of corresponding gene fragments will be produced, and these gene fragments will exist in the cell for a long time, floating randomly and disorderly. Who knows what unknown things might happen?

Therefore, in the long run, this will naturally lead to unknown hidden dangers. So although this method is quick, it is actually quite dangerous.

The third method for editing genes in cells throughout the body is the ribonucleoprotein RNP Complex Transfection.

The so-called RNP Complex Transfection involves forming RNP Complex in vitro with sgRNA, crRNA, and purified Cas9 protein.

The RNP Complex is then introduced into cells via liposomes or electroporation to complete the editing of cellular genes.

Its advantage is that the RNP Complex, once inside the cell, can function directly without going through the process of transcription and translation.

Furthermore, because its existence time is relatively short, it will automatically degrade within 24 hours, which significantly reduces the risk of off-target effects and unknown hidden dangers, thus greatly improving safety.

Therefore, gene therapy products that officially entered clinical trials in 2024 in the previous life usually used the NP complex delivery method.

This technology also has two drawbacks. The first drawback is that the design and manufacturing cost of the RNP Complex is extremely high, which ultimately leads to the problem that the treatment price cannot be reduced.

The second drawback is that the gene therapy drugs produced must be used as soon as possible.

Otherwise, due to the inherent defects of the RNP Complex, it will automatically degrade into useless waste over time.

Of course, the fact that the product must be used as soon as it is manufactured is not a big problem; patients can simply come to the area near the factory for treatment.

This can actually boost the economy of areas such as Xiaohe Town, Liancheng, and Zhancheng, so it's not a disadvantage but rather an advantage.

So the only real headache is the extremely high manufacturing cost.

After all, traditional Viral Transduction Method only requires editing one virus, and the edited virus will then reproduce on its own, thus enabling the continuous and low-cost production of 'gene therapy agents'.

The only way to produce RNP Complex is through chemical synthesis.

Any error in temperature, vibration, or pressure difference could lead to the failure of chemical synthesis.

This requires extremely high control precision, as well as precise chemical coupling and base pairing techniques; it's fair to say that producing this would be a disaster.

But this disaster is for others; for Xingtu Gene Company that possesses the Artificial Intelligence Jarvis that can control production equipment to produce automatically, it is nothing.

Therefore, this method is actually the most suitable for Xingtu Gene Company, as it has high editing efficiency, is safe, has few hidden dangers, and does not cause a huge immune response.

Finally, the extremely high difficulty in chemical formation prevents most unqualified plagiarists from copying the RNP Complex, making it impossible for them to do so even if they wanted to.

As for companies with the capability to produce, they dare not produce on a large scale, because they are certainly afraid that Xingtu Gene Company will sue them for patent infringement and they will lose everything.

It can be said that this RNP Complex, which is extremely difficult to manufacture, is a disaster for the counterfeit pharmaceutical factories in India.

Even if the counterfeit pharmaceutical companies in India wanted to copy his RNP Complex, they couldn't do it. This unique situation naturally made Xingtu Gene Company very wealthy!

Of course, based on the knowledge Lin Feng had, the CRISPR/Cas9 Gene Editing Technology was not yet complete.

Following the whole-body cell gene editing section are the sections on reducing the immune response and the auxiliary section on how to introduce the RNP Complex.

Therefore, Lin Feng's knowledge at this time consists of four main parts, which complement each other.

When these four technologies are combined, the CRISPR/Cas9 Gene Editing Technology is successfully put into practical use.

From then on, they relied on the truly practical CRISPR/Cas9 Gene Editing Technology.

It can not only knock out a segment of a gene in the human body, but also knock in a newly edited gene segment into the original position!

This also means that from now on, Lin Feng can not only solve the SIV Monkey Immunodeficiency Virus through this method, but also the human AIDS virus.

This includes other Hepatitis B virus, Herpes Simplex Virus, and other genetic diseases caused by gene defects.

A range of genetic diseases, such as Cystic Fibrosis, hereditary Thalassemia, thalassemia, and leukemia, can be treated.

These are other non-genetic diseases, such as immune system diseases and nervous system diseases.

Even other conditions like AIDS, diabetes, and cancer may be treated with suppression therapy.

After all, so-called cancer is nothing more than a disordered mutation of cell genes, resulting in unnatural and rampant proliferation.

This forces humans to either remove or damage cancerous cells, eventually leading to a sudden and fatal death when the cancer becomes uncontrollable.

However, with the CRISPR/Cas9 Gene Editing Technology, it is now possible to target specific gene segments in cancer cells, eliminate those gene segments, and inactivate the genome.

It can even modify the erroneous gene segment to restore it to a normal state, thereby causing cancerous cells to return to a normal cell state.

These are all theoretically possible, but of course, it would require a large number of researchers to study them.

Because the CRISPR/Cas9 Gene Editing Technology that Lin Feng currently possesses can only knock out a specific gene segment in the genes of cells throughout the body.

Then, the artificially edited gene fragment is inserted into the original position to complete the gene editing.

Among these methods, directly knocking out gene fragments in cancerous cells, thereby causing the cells to become inactive and die, is relatively easy to achieve.

However, it is quite difficult to restore the cell to normal after knocking out the abnormal gene segment and then knocking in the normal gene segment.

After all, who knows what the patient's normal gene segments look like?

Moreover, destruction is easy but repair is difficult; achieving this is far more difficult than destroying abnormal gene fragments.

While it is difficult, it is undeniable that it is possible to achieve, given that Xingtu Gene Company has the Artificial Intelligence Jarvis.

It is very difficult for humans to analyze massive amounts of genomic data and then deduce what normal gene segments look like.

This does not mean that the Artificial Intelligence Jarvis is unable to analyze genomic data and then deduce what normal gene segments look like.

Finally, the normal gene fragment is knocked into the cell's gene, thereby restoring the cell to a normal state.

Of course, these are all things for the future. Treating those diseases is destined to be a long process.

After all, you have to conduct clinical trials before that, and the whole process goes from project initiation and research to clinical trials.

It will definitely take a year, but it could take two or even three years.

It all depends on how difficult the specific medical technology is to develop and how quickly the higher authorities approve clinical trials.

Nodding in satisfaction, Lin Feng picked up a test tube labeled 'First-generation Gene Enhancement Potion', a thoughtful expression on his face.

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Lin Feng
Jarvis

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS